Washington, DC – January 20, 2021 – Friends of Cancer Research (Friends) would like to applaud President Biden for selecting Dr. Janet Woodcock to serve as acting Commissioner of the U.S. Food and Drug Administration (FDA).  We look forward to working with Dr. Woodcock in her new role as the acting lead at the FDA, and should he choose, as President Biden’s permanent Commissioner. 

“Dr. Woodcock has been a pivotal figure at the FDA for decades and there is no one better qualified than her to direct the Agency at this crucial time,” said Friends of Cancer Research Chair & Founder, Ellen Sigal. “We have no doubt that Dr. Woodcock will not only continue to steer the Agency in the right direction, but that she will actively work to advance innovative science and ensure FDA maintains its gold-standard of reviewing and approving new therapies, vaccines, and treatments for patients.” 

Friends is deeply grateful to Dr. Woodcock for her many years of service at the FDA and her recent work as a lead at Operation Warp Speed. Dr. Woodcock as acting FDA Commissioner solidifies the respect of FDA and its career scientists. 

About Friends of Cancer Research
Friends of Cancer Research (Friends) is working to accelerate policy change, support groundbreaking science, and deliver new therapies to patients quickly and safely. We unite scientists, pharmaceutical companies, and policy makers with shared trust and guide them toward meaningful cooperation. This collaboration among partners from every healthcare sector ultimately drives advances in science, policy, and regulation that speed life-saving treatments to patients. For more information, please visit www.friendsofcancerresearch.org/.